1B-LSD

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Keith D (talk | contribs) at 21:05, 29 May 2020 (Fix PMC warnings). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

1B-LSD
Legal status
Legal status
Identifiers
  • (6aR,9R)-N,N-diethyl-7-methyl-4-butanoyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
CAS Number
ChemSpider
Chemical and physical data
FormulaC24H31N3O2
Molar mass393.531 g·mol−1
3D model (JSmol)
  • CN1[C@](C2=C[C@@H](C(N(CC)CC)=O)C1)([H])CC3=CN(C(CCC)=O)C4=C3C2=CC=C4
  • InChI=1S/C24H31N3O2/c1-5-9-22(28)27-15-16-13-21-19(18-10-8-11-20(27)23(16)18)12-17(14-25(21)4)24(29)26(6-2)7-3/h8,10-12,15,17,21H,5-7,9,13-14H2,1-4H3/t17-,21-/m1/s1
  • Key:SVRFNPSJPIDUBC-DYESRHJHSA-N

1B-LSD (N1-butyryl-lysergic acid diethylamide) is an acylated derivative of lysergic acid diethylamide (LSD), which has been sold as a designer drug.[1] In tests on mice it was found to be an active psychedelic, though with only around 1/7th the potency of LSD itself.[2][3][4]

Legal status

1B-LSD is illegal in Singapore.[5] Sweden's public health agency suggested classifying 1B-LSD as a hazardous substance, on June 24, 2019.[6]

See also

References

  1. ^ Tsochatzis, Emmanouil; Lopes, Joao Alberto; Reniero, Fabiano; Holland, Margaret; Åberg, Jenny; Guillou, Claude (February 2020). "Identification of 1-Butyl-Lysergic Acid Diethylamide (1B-LSD) in Seized Blotter Paper Using an Integrated Workflow of Analytical Techniques and Chemo-Informatics". Molecules. 25 (3). doi:10.3390/molecules25030712. ISSN 1420-3049. PMC 7037844. PMID 32045999.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  2. ^ Wagmann, Lea; Richter, Lilian H. J.; Kehl, Tobias; Wack, Franziska; Bergstrand, Madeleine Pettersson; Brandt, Simon D.; Stratford, Alexander; Maurer, Hans H.; Meyer, Markus R. (July 2019). "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures". Analytical and Bioanalytical Chemistry. 411 (19): 4751–4763. doi:10.1007/s00216-018-1558-9. ISSN 1618-2650. PMID 30617391.
  3. ^ Brandt, Simon D.; Kavanagh, Pierce V.; Westphal, Folker; Stratford, Alexander; Elliott, Simon P.; Dowling, Geraldine; Wallach, Jason; Halberstadt, Adam L. (May 2019). "Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD)". Drug Testing and Analysis. 11 (8): 1122–1133. doi:10.1002/dta.2613. ISSN 1942-7611. PMC 6899222. PMID 31083768.
  4. ^ Halberstadt, Adam L.; Chatha, Muhammad; Klein, Adam K.; McCorvy, John D.; Meyer, Markus R.; Wagmann, Lea; Stratford, Alexander; Brandt, Simon D. (November 2019). "Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)". Neuropharmacology: 107856. doi:10.1016/j.neuropharm.2019.107856. ISSN 0028-3908. PMID 31756337.
  5. ^ "Misuse of Drugs Act - Singapore Statutes Online". sso.agc.gov.sg.
  6. ^ "Åtta ämnen föreslås klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. 24 June 2019.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=1B-LSD&oldid=959643270"